Anixa Biosciences Inc

Anixa Biosciences Inc has a market capitalization of $96.9 million and a price-to-book ratio of 4.1, indicating a premium valuation relative to its book value. The company's liquidity position is strong, with a current ratio of 14.4, suggesting it has ample short-term assets to cover its liabilities. However, the company has no long-term debt and a cash and equivalents balance of $995,000, which may limit its ability to fund operations without external financing.

The company's profitability metrics are negative, with a return on equity of -13.29% and a return on assets of -12.89%, indicating that it is not generating returns for shareholders or effectively utilizing its assets. The operating income of -$3.47 million and net income of -$3.14 million further underscore the company's unprofitable operations. These figures are below the industry median for profitability metrics, suggesting that Anixa Biosciences Inc is underperforming its peers in terms of generating returns.

Anixa Biosciences Inc does not disclose specific revenue by segment or geographic region, making it difficult to assess the concentration of its revenue sources. The lack of detailed segment reporting implies that the company's financial performance is not diversified, which could pose a risk if a particular product or market experiences a downturn.

The company's growth trajectory is uncertain, as it has reported zero revenue and negative operating and net income in the latest financial period. Analysts have provided a mean price target of $10.00 and a median price target of $9.50, with four "buy" recommendations and no "strong buy" or "hold" ratings. These estimates suggest that analysts see potential for the stock to appreciate, but the absence of revenue and ongoing losses indicate that the company is in an early-stage or development phase.

The risk assessment for Anixa Biosciences Inc indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow of -$3.77 million and the absence of long-term debt suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The company's equity base of $23.62 million and total assets of $24.36 million provide a buffer, but the lack of revenue and ongoing losses could pressure the need for further financing.

Recent events and filings do not indicate any significant developments that would impact the company's financial position or strategic direction. The company remains in a development phase, and its future success will depend on its ability to advance its pipeline and achieve commercialization of its products.

Analysts project 181.7% upside to a mean price target of $10.00, reflecting strong buy recommendations from four analysts.

The company maintains a zero long-term debt balance across all reported fiscal years, minimizing leverage risk.

Anixa Biosciences reports a current ratio of 8.54, indicating strong short-term liquidity and low credit risk.

Cash conversion metrics are above the cohort median, suggesting better capital preservation than peers.

The company recorded net losses of $10.9 million in FY2026, continuing a pattern of significant annual deficits.

Revenue was zero in FY2025 and FY2026, indicating a lack of commercial product sales or recurring income.

Operating income declined to a loss of $11.7 million in FY2026, highlighting persistent operational unprofitability.

Return on invested capital is negative at -14.68%, demonstrating poor capital efficiency over the period.

Free cash flow was negative $13.7 million in FY2023, showing heavy cash burn during that period.

Revenue $0.00; Operating income +19,8% YoY.

• ▍Revenue $0.00
• ▍Operating income +19,8% YoY
• ▍Net income +19,4% YoY

Revenue $0.00; Operating income +9,1% YoY.

• ▍Revenue $0.00
• ▍Operating income +9,1% YoY
• ▍Net income +6,5% YoY

Revenue $0.00; Operating income +32,2% YoY.

• ▍Revenue $0.00
• ▍Operating income +32,2% YoY
• ▍Net income +31,1% YoY

Revenue $0.00; Operating income +13,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +13,4% YoY
• ▍Net income +11,1% YoY

Revenue $0.00; Operating income -$3.4M.

• ▍Revenue $0.00
• ▍Operating income -$3.4M

Revenue $0.00; Operating income -$3.2M.

• ▍Revenue $0.00
• ▍Operating income -$3.2M

Revenue $0.00; Operating income -$3.6M.

• ▍Revenue $0.00
• ▍Operating income -$3.6M

Revenue $0.00; Operating income -$3.5M.

• ▍Revenue $0.00
• ▍Operating income -$3.5M

Revenue $0.00; Operating income +15,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +15,4% YoY
• ▍Net income +13,0% YoY

Revenue $0.00, −100,0% YoY; Operating income −25,6% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −25,6% YoY
• ▍Net income −28,0% YoY

Revenue $210.0k; Operating income +20,6% YoY.

• ▍Revenue $210.0k
• ▍Operating income +20,6% YoY
• ▍Net income +27,8% YoY
• ▍Net margin -4671.9%

Revenue $0.00, −100,0% YoY; Operating income −5,6% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −5,6% YoY
• ▍Net income −5,0% YoY
• ▍Free cash flow −5,1% YoY